治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin

doi:10.6040/j.issn.1671-7554.0.2025.0700

摘要/Abstract

摘要： Telisotuzumab Vedotin是靶向作用于c-Met蛋白的抗体药物偶联物。2025年5月14日,美国食品药品监督管理局通过加速评审,批准Telisotuzumab Vedotin用于治疗既往接受过全身治疗的局部晚期或转移性非鳞状非小细胞肺癌且c-Met蛋白高表达的成年患者。Telisotuzumab Vedotin是首个针对c-Met蛋白的抗体药物偶联物。本文主要介绍其作用机制、药动学、临床研究及安全性。

关键词: Telisotuzumab Vedotin, 抗体药物偶联物, c-Met蛋白, 非小细胞肺癌, 作用机制, 临床研究

Abstract: Telisotuzumab Vedotin is an antibody-drug conjugate targeting c-Met protein. Telisotuzumab Vedotin was approved for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein expression by the U.S. Food and Drug Administration on May 14, 2025. Telisotuzumab Vedotin is the first c-Met-targeted antibody-drug conjugate approved for clinical use.The mechanism,pharmacokinetics,clinical research and safety of Telisotuzumab Vedotin were reviewed in this article.

Key words: Telisotuzumab Vedotin, Antibody-drug conjugate, c-Met protein, Non-small cell lung cancer, Action mechanism, Clinical research

中图分类号:

R979.1

黄佩文,王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.

HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein[J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130.

参考文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] American Cancer Society.Cancer facts & figures 2025[EB/OL].(2025-05-16)[2025-06-22]. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf
[3] 艾静, 杜玉萍, 王崇霖, 等. 197例早期非小细胞肺癌患者营养风险状况及其相关因素[J]. 卫生研究, 2025, 54(3): 444-448. AI Jing, DU Yuping, WANG Chonglin, et al. Nutritional risk investigation and related factors of 197 patients with early-stage non-small cell lung cancer[J].Journal of Hygiene Research, 2025, 54(3): 444-448.
[4] Tsakonas G, Botling J, Micke P, et al. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer[J]. Lung Cancer, 2019, 133: 69-74. doi: 10.1016/j.lungcan.2019.04.028
[5] Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression[J]. J Clin Oncol, 2016, 34(7): 721-730.
[6] 高洋, 项鹏程, 岳林, 等. 非小细胞肺癌中PD-L1与C-Met基因表达的相关性研究[J]. 诊断病理学杂志, 2021, 28(12): 1066-1071.
[7] 赵博晨, 路丹. c-Met 在肺癌中的研究进展[J]. 现代肿瘤医学, 2022, 30(1): 174-178. ZHAO Bochen, LU Dan. Research progress of c-Met in lung cancer[J]. Modern Oncology, 2022, 30(1): 174-178.
[8] Zhan ST, Li JF, Cheng B, et al. Landscape of c-Met overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data[J]. Ther Adv Med Oncol,2024,16:17588359241279715. doi: 10.1177/17588359241279715
[9] Bai QM, Shi XH, Zhou XY, et al. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer[J]. Ther Adv Med Oncol, 2024, 16: 17588359231216096. doi: 10.1177/17588359231216096
[10] FDA. FDA grants accelerated approval to Emrelis[EB/OL].(2025-05-14)[2025-06-22]. https://www.drugs.com/newdrugs/fda-grants-accelerated-approval-emrelis-telisotuzumab-vedotin-tllv-non-small-cell-lung-cancer-c-met-6519.html
[11] Strickler JH, Weekes CD, Nemunaitis J, et al. First-in-human phase I, dose-escalation and -expansion study of Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(33): 3298-3306.
[12] Wang JY, Anderson MG, Oleksijew A, et al. ABBV-399, a c-Met antibody drug conjugate that targets both MET amplified and c-Met overexpressing tumors, irrespective of MET pathway dependence[J]. Clin Cancer Res, 2017, 23(4): 992-1000.
[13] Mer AH, Mirzaei Y, Misamogooe F, et al. Progress of antibody-drug conjugates(ADCs)targeting c-Met in cancer therapy; insights from clinical and preclinical studies[J]. Drug Deliv Transl Res, 2024, 14(11): 2963-2988.
[14] 李雨凝, 苏佳琳, 罗永忠, 等. 抗体药物偶联物治疗非小细胞肺癌的研究进展和展望[J]. 肿瘤药学, 2024, 14(4): 411-419. LI Yuning, SU Jialin, LUO Yongzhong, et al. Research progress and prospect of antibody-drug conjugates in the treatment of non-small cell lung cancer[J]. Anti-Tumor Pharmacy, 2024, 14(4): 411-419.
[15] 沈娟, 刘炬, 于蒙蒙, 等. 抗体偶联药物组成及质量控制概述[J]. 解放军药学学报, 2025, 38(2): 209-215. SHEN Juan, LIU Ju, YU Mengmeng, et al. A surveyof composition and quality control of antibody-drug conjugates[J]. Pharmaceutical Journal of Chinese Peoples Liberation Army, 2025, 38(2): 209-215.
[16] Kwak Y, Kim SI, Park CK, et al. C-MET overexpression and ampliffcation in gliomas[J]. Int J Clin Exp Pathol, 2015, 8(11): 14932-14938.
[17] Remon J, Hendriks LEL, Mountzios G, et al. MET alterations in NSCLC-current perspectives and future challenges[J]. J Thorac Oncol, 2023, 18(4): 419-435.
[18] Wang JY, Goetsch L, Tucker L, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification[J]. BMC Cancer, 2016, 16: 105. doi: 10.1186/s12885-016-2138-z
[19] Gonzalez A, Broussas M, Beau-Larvor C, et al. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors[J]. Int J Cancer, 2016, 139(8): 1851-1863.
[20] 罗梦珺, 张丽瑾, 陈涛. c-Met在非小细胞肺癌中的作用及中药干预的研究进展[J]. 生命的化学, 2021, 41(1): 84-90. LUO Mengjun, ZHANG Lijin, CHEN Tao. Role of c-Met in non-small cell lung cancer and research progress in the intervention of traditional Chinese medicine[J]. Chemistry of Life, 2021, 41(1): 84-90.
[21] Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced non-squamous EGFR-wildtype NSCLC in the Phase 2 LUMINOSITY trial[J]. J Clin Oncol, 2024, 42(25): 3000-3011.
[22] Horinouchi H, Cho BC, Camidge DR, et al. Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer(NSCLC)after progression on prior osimertinib[J]. Ann Oncol, 2025, 36(5): 583-591.
[23] FDA. EMRELISTM(telisotuzumab vedotin-tllv)for injection, for intravenous use[EB/OL].(2025-05-14)[2025-06-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf
[24] Camidge DR, Barlesi F, Goldman JW, et al. A phase 1b study of telisotuzumab vedotin in combination with nivolumab in patients with NSCLC[J]. JTO Clin Res Rep, 2021, 3(1): 100262. doi: 10.1016/j.jtocrr.2021.100262
[25] Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib study of Telisotuzumab Vedotin in combination with erlotinib in patients with c-Met protein-expressing non small-cell lung cancer[J]. J Clin Oncol, 2023, 41(5): 1105-1115.
[26] NIH. A Study evaluating the safety, pharmacokinetics(PK), and preliminary efficacy of ABBV-399 in participants with advanced solid tumors[EB/OL].(2025-02 -26)[2025-06-22]. https://clinicaltrials.gov/study/NCT02099058?term=Telisotuzumab%20Vedotin&rank=6
[27] NIH. A study to assess disease activity and adverse events of intravenous(IV)Telisotuzumab Vedotin compared to IV docetaxel in adult participants with previously treated non-squamous non-small cell lung cancer(NSCLC)[EB/OL].(2025-05-29)[2025-06-22. https://clinicaltrials.gov/study/NCT04928846?term=Telisotuzumab%20Vedotin&rank=5
[28] NIH. A study to assess adverse events and how intravenously(IV)infused Telisotuzumab Vedotin(ABBV-399)moves through the body as a monotherapy in adult participants with previously treated non-squamous non-small cell lung cancer(NSCLC)[EB/OL].(2025-05-29)[2025-06-22]. https://clinicaltrials.gov/study/NCT06568939?term=Telisotuzumab%20Vedotin&rank=2&tab=table
[29] Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells[J]. Cancer Immunol Res, 2014, 2(8): 741-755.

相关文章 15

[1]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[2]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[3]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[4]	刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[5]	王凤燕,梁振宇,李雪萍,陈荣昌. 慢性阻塞性肺疾病近年临床研究热点[J]. 山东大学学报 (医学版), 2024, 62(5): 7-15.
[6]	张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[7]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[8]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[9]	马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68.
[10]	刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43.
[11]	丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98.
[12]	郭曼,刘鹏,龙麟. 防纤汤对放射性肺炎大鼠的影响及作用机制[J]. 山东大学学报 (医学版), 2021, 59(8): 53-60.
[13]	余雪源,张硕,燕芳芳,苏德振. 采用清肺排毒汤联合西药43例与单用西药46例的新型冠状病毒肺炎临床疗效比较[J]. 山东大学学报 (医学版), 2020, 58(12): 47-53.
[14]	刘小璟,夏西燕,肖珂,陈文丹,庄学伟. 外泌体lncRNA OGFRP1在84例非小细胞肺癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2020, 58(11): 71-75.
[15]	高源,季伟,肖丹,刘井,彭丹冰,季春. 基于网络药理学预测沙苑子的抗炎作用机制[J]. 山东大学学报 (医学版), 2019, 57(9): 59-68.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed